FULC
NASDAQFulcrum Therapeutics Inc.
Price$7.12-0.12 (-1.66%)
01:30 PM07:45 PM
News · 26 weeks50+250%
2025-11-022026-04-26
Mix2590d
- Other7(28%)
- SEC Filings7(28%)
- Insider6(24%)
- Earnings3(12%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form DEFA14A filed by Fulcrum Therapeutics Inc.DEFA14A - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- SECSEC Form DEF 14A filed by Fulcrum Therapeutics Inc.DEF 14A - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- SECSEC Form 10-Q filed by Fulcrum Therapeutics Inc.10-Q - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- SECFulcrum Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- PRFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Dosed first patient in an open-label, long-term dosing trial evaluating the long-term safety and durability of response to pociredir in participants previously enrolled in the PIONEER trial ― ― Appointed Josh Lehrer, M.D., M.Phil., FACC, an experienced leader in sickle cell disease drug development, to the Board of Directors ― ― Chief Financial Officer, Alan Musso
- PRFulcrum Therapeutics Appoints Josh Lehrer to its Board of DirectorsCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director. Dr. Lehrer is a physician-scientist and biotechnology executive with more than two decades of clinical development experience across all stages of drug development. He currently serves as Chief Executive Officer and a member of the board of directors of Marea Therapeutics, a clinical-stage biotechnology company
- PRFulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ETCAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
- PRMedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell DiseaseCAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle cell disease and their caregivers, and Fulcrum Therapeutics Inc. (Fulcrum) (NASDAQ:FULC), a leader in advancing therapies for underserved patient populations, today announced a new partnership designed to help streamline and expedite emergency department (ED) care for people living with sickle cell disease (SCD) through rapid access to patient-specific care plans. Individuals living with SCD, an inherited blood disorder,
- PRFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 34,000 options to pur
- PRFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET. The webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics' webs
- SECSEC Form S-8 filed by Fulcrum Therapeutics Inc.S-8 - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- SECSEC Form 10-K filed by Fulcrum Therapeutics Inc.10-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- SECFulcrum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- PRFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029 ― CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therap
- PRFulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
- PRFulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseCAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for
- PRFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 70,000 options to purc
- INSIDERAmendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Musso Alan A4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer Tourangeau Greg4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Oltmans Curtis Gale4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERDirector Gould Robert J sold $160,857 worth of shares (15,000 units at $10.72), decreasing direct ownership by 3% to 454,864 units (SEC Form 4)4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Officer Sapir Alex4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
FULC FAQ
7 questionsWhat does Fulcrum Therapeutics Inc. do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with...Where does FULC stock trade?
Fulcrum Therapeutics Inc. (FULC) is listed on NASDAQ.What sector and industry is FULC in?
Fulcrum Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Fulcrum Therapeutics Inc. go public?
Fulcrum Therapeutics Inc. (FULC) completed its IPO in 2019.What are analysts saying about FULC?
Fulcrum Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $2000.00 price target on 2026-01-12. Recent price targets range from $400.00 to $2000.00.What companies are similar to FULC?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare FULC side-by-side with any of them on Quantisnow.How can I track FULC on Quantisnow?
Quantisnow aggregates Fulcrum Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FULC to receive live email and push alerts on every new disclosure.